DadFinStart your free week
DadFin › Stocks › Healthcare › AZTA

Azenta, Inc. (AZTA) stock score

Healthcare · Medical Instruments & Supplies · United States

$37.72 ▲ +4.78% today

77.3
Dad Score, out of 100
good

Azenta, Inc. (AZTA) is a Medical Instruments & Supplies company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 77.3 out of 100 on the Dad Score, a good reading that places the business ahead of 77% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #201 of 974. Its strongest axes are price action, conviction and liquidity; its weakest are valuation and risk.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Average
Growth
Average
Price action
Strong
Risk
Below average
Conviction
Strong
Liquidity
Above average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)66.0×
Dividend yield0.00%
Return on capital-4.8%
Operating margin-2.3%
Revenue growth (YoY)+3.5%
FCF yield2.7%
Net debt / EBITDA-8.24×
Piotroski F-Score5 / 9
52-week change+21.9%
Market cap$1.7B
Next earningsNov 20, 2026

What subscribers see on AZTA

Start your free weekSubscriber? Open the full research →

Medical Instruments & Supplies peers

StockCompanyDad ScoreBandMarket cap
ISRGIntuitive Surgical, Inc.87.0strong$140.4B
BDXBecton, Dickinson and Company69.8middling$48.2B
MDLNMedline Inc.98.2strong$47.9B
ALCAlcon Inc.64.6middling$30.8B
RMDResMed Inc.94.3strong$30.8B
WSTWest Pharmaceutical Services, Inc.90.1strong$25.7B
SOLVSolventum Corporation71.9good$15.0B
BAXBaxter International Inc.40.5middling$12.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.